Ibutilide: An antiarrhythmic agent for the treatment of atrial fibrillation or flutter

Annals of Pharmacotherapy

Volumn 33, Issue 1, 1999, Pages 38-47

  Howard, Patricia A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Atrial flutter; Ibutilide

Indexed keywords

IBUTILIDE; PROCAINAMIDE; SOTALOL;

CARDIOVERSION; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM;

EID: 0032904259     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18097     Document Type: Review

References (58)

1. Feinberg WM, Blackshear JL, Laupacia A. Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995;155: 469-73.
2. Albers GW. Atrial fibrillation and stroke: three remaining questions. Arch Intern Med 1994;154:1443-8.
3. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-7.
4. Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. Hospitalisation for arrhythmias in the United States: importance of atrial fibrillation (abstract). J Am Coll Cardiol 1992;19:41A.
5. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 1962;140:705-58.
6. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93:1262-77.
7. Daoud E, Niebauer M, Bogun F, Castenelli M, Chan KK, Morady F. Atrial fibrillation induced shortening of atrial refractoriness (abstract). Circulation 1995;92(suppl 1):I104.
8. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. Circulation 1995;92:1954-68.
9. Camm AJ. Obel OA. Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol 1996;78(suppl 8A):3-11.
10. Anderson JL. Acute treatment of atrial fibrillation and flutter. Am J Cardiol 1996;78(suppl 8A):17-21.
11. Repique LJ, Shah SN, Marais GE. Atrial fibrillation 1992, management strategies in flux. Chest 1992;101:1095-103.
12. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992; 326:1264-71.
13. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Anti-thrombotic therapy in atrial fibrillation. Chest 1995:108(suppl):352S-9S.
14. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996;125:311-23.
15. Package insert. Corvert (ibutilide fumarate). Kalamazoo, MI: Pharmacia & Upjohn, January 1996.
16. Chen BP, Chow MSS, Kluger J. Focus on ibutilide. Formulary 1996;31: 570-6.
17. Cimini MG, Brunden MNm Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent and its action on isolated rabbit myocardium. Eur J Pharmacol 1992;222:93-8.
18. Lee KS, Tsai TD, Lee EW. Membrane activity of class III antiarrhythmic compounds: a comparison between ibutilide, d-sotalol. E-4031, sematilide and dofetlide. Eur J Pharmacol 1993;234:43-53.
19. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992;262:99-108.
20. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996;78(suppl 8A):12-6.
21. + current (Ikr) in AT-1 cell. Circulation 1995;91:1799-806.
22. Lynch JJ Jr, Baskin EP, Nutt EM, Guinosso PJ, Hamill T, Salata JJ, et al. Comparison of binding to rapidly activating delayed rectifier K+ channel, Ikr and effects on myocardial refractoriness for class III antiarrhythmic agents. J Cardiovasc Pharmacol 1995;25:336-40.
23. Roden DM. Ibutilide and the treatment of atrial arrhythmias (editorial). Circulation 1996;94:1499-502.
24. Buchanan LV, Turcotte UM, Kabell G, Gibson JK. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993;33:10-4.
25. Nabih MA, Prcevski P, Fromm BS, Lavine SJ, Elnabtity M, Munir A, et al. Effect of ibutilide, a new class III agent on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. Pacing Clin Electrophysiol 1993;16:1975-83.
26. VanderLugt JT, Gaylor SK, Wakefield LK, Jungbluth GL, Walters RR, Kabell GG. Effects of ibutilide fumarate, a new class III antiarrhythmic agent in man (abstract). Clin Pharmacol Ther 1991;49:188.
27. Jungbluth GL, Della-Coletta AA, VanderLugt JT. Evaluation of the pharmacokinetics and pharmacodynamics of ibutilide fumarate and its enantiomers in healthy male volunteers (abstract). Pharm Res 1991;8 (suppl 10):S249.
28. Foster RH, Wilde MI, Markham A. Ibutilide: a review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997;54:312-30.
29. Stambler BS, Beckman KJ, Kadish AH, Camm JA, Ellenbogen KA, Perry KT, et al. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997;80:458-63.
30. Guo GBF, Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 1996;27:1083-9.
31. Nattel S, Bourne G, Talajic M. Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. J Cardiovasc Electrophysiol 1997;8:469-80.
32. Hondeghem LM, Snydets DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse dependence. Circulation 1990;81:686-90.
33. c interval prolongation induced by the class III antiarrhythmic drug ibutilide (abstract). Clin Pharmacol Ther 1996;59: 164.
34. DiMarco JP. Cardioversion of atrial flutter by intravenous ibutilide, a new class III antiarrhythmic agent (abstract). J Am Coll Cardiol 1991;17: 324A.
35. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC, Meissner MD, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-6.
36. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21.
37. Mattioni T, Denker S, Riggio D, Smith J, Welch S, Perry K, et al. Efficacy and safety of intravenous ibutilide in the treatment of atrial flutter and atrial fibrillation following valvular or coronary artery bypass surgery (abstract). Pacing Clin Electrophysiol 1997;20:1059.
38. Stambler BS, Wood MA, Belz MK, Sperry RE, VanderLugt JT, Ellenbogen KA, et al. Electrophysiologic determinants of pharmacologic conversion of human atrial fibrillation and flutter: enhanced efficacy of ibutilide a new class III antiarrhythmic drug (abstract). Circulation 1993;88: 1445.
39. Volgman AS, Stambler BS, Kappagoda C, Carberry PA, Dunn GH, Perry KT, et al. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter (abstract). Pacing Clin Electrophysiol 1996;19:608.
40. Crijns HJGM, Golitsyn SR, Ruda MY, Stangi K, Harry JD, VanderLugt JT, et al. Superiority of ibutilide over dl-sotalol in termination of atrial fibrillation and flutter: results of a multinational trial (abstract). Eur Heart J 1996:17(suppl):583.
41. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TED. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
42. Fenster PE, Comess KA, Marsh R, Kutzenberg C, Hager D. Conversion of atrial fibrillation to sinus rhythm by acute intnivenous procainamide infusion. Am Heart J 1983;106:501-4.
43. Madrid AH, Moro C, Huerta EM, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993;14:1127-31.
44. Halpern SW, Ellrodt G, Singh BN, Manel WJ. Efficacy of intravenous procainamide infusion on convening atrial fibrillation in sinus rhythm. Br Heart J 1980;44:589-95.
45. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L, Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the sotalol-digoxin-quinidine trial). Am J Cardiol 1995; 76:495-8.
46. Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996;77:960-6.
47. McCarthy C, Varghese PJ, Barritt DW. Prognosis of atrial arrhythmias treated by electrical counter shock therapy. A three-year follow-up. Br Heart J 1969;31:496-500.
48. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988;9:284-90.
49. Hartel G, Louhija A, Konttinen A, Halonen PI. Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J 1970;32:57-60.
50. Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. Br Heart J 1971;33:518-21.
51. Kowey PR, VanderLugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 1996;78(suppl 8A):46-52.
52. Van Gelder IC, Crijns JGM. Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm. Pacing Clin Electrophysiol 1997; 20(pt II):2675-83.
53. Ellenbogen K, VanderLugt JT, Robbins I, Kowey P. Overall safety experience with intravenous ibutilide (abstract). Pacing Clin Electrophysiol 1996;19:608.
54. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
55. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion and early after depolarizations. Cardiovasc Res 1993;27:2186-93.
56. 1998 Drug topics red book, Montvale, NJ: Medical Economics Co., 1998.
57. Zarkin GA, Bala MV, Calingaert B, VanderLugt JT. The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm. Am J Man Care 1997;3:1387-94.
58. Singletary TJ, Malone DC, Wortman GC. Cost-effectiveness analysis of pharmacologic cardioversion for ambulatory atrial arrhythmias (abstract). Pharmacotherapy 1997;17:1106.